Clinical trials
Phase 1 Nasopharyngeal Neoplasms trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2009 | 1 |
| 2014 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 10 |
| Terminated | 2 |
| Active, not recruiting | 2 |
| Withdrawn | 1 |
| Recruiting | 1 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 3 |
| Baylor College of Medicine | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| Abramson Cancer Center at Penn Medicine | 1 |
| City of Hope Medical Center | 1 |
| Dana-Farber Cancer Institute | 1 |
| Incyte Corporation | 1 |
| National Institutes of Health Clinical Center (CC) | 1 |
| Novartis Pharmaceuticals | 1 |
| Poseida Therapeutics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Nasopharyngeal Neoplasms | 18 |
| Head and Neck Neoplasms | 9 |
| Squamous Cell Carcinoma of Head and Neck | 7 |
| Carcinoma, Non-Small-Cell Lung | 6 |
| Hypopharyngeal Neoplasms | 6 |
| Laryngeal Neoplasms | 6 |
| Ovarian Neoplasms | 6 |
| Mouth Neoplasms | 5 |
| Oropharyngeal Neoplasms | 5 |
| Breast Neoplasms | 4 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.